Coexisting dysbetalipoproteinemia and familial hypercholesterolemia: Clinical and laboratory observations

Atherosclerosis

Volumn 148, Issue 1, 2000, Pages 113-124

  Carmena, Rafael ^a   Roy, Madeleine ^b   Roederer, Ghislaine ^b   Minnich, Anne ^b   Davignon, Jean ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Atherosclerotic vascular disease; Dysbetalipoproteinemia; Familial hypercholesterolemia; Phenotypic expression

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGAR GEL ELECTROPHORESIS; AGED; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; FEMALE; GENETIC ANALYSIS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PERIPHERAL VASCULAR DISEASE; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SMOKING; XANTHOMA;

ADULT; AGED; ALLELES; APOLIPOPROTEIN E2; APOLIPOPROTEINS E; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CHOLESTEROL, LDL; FEMALE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPERLIPOPROTEINEMIA TYPE III; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; PREVALENCE; RECEPTORS, LDL; REFERENCE VALUES;

EID: 0033991519     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00212-9     Document Type: Article

References (39)

1. Brewer H.B. Jr., Zech L.A., Gregg R.E., Schwartz D., Schaefer E.J. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann. Intern. Med. 98:1983;623-640.
2. Havel R.J. Familial dysbetalipoproteinemia. New aspects of pathogenesis and treatment. Med. Clin. North Am. 66:1982;441-454.
3. Mahley R.W., Rall S.C. Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The Metabolic and Molecular Bases of Inherited Disease. Seventh edition:1995;1953-1980 McGraw-Hill, New York.
4. Davignon J. Apolipoprotein E polymorphism and atherosclerosis. Schwartz C.J., Born G.V.R. New Horizons in Coronary Heart Disease. 1993;5.1-5.21 Current Science, London.
5. Goldstein J.L., Hobbs H.H., Brown M.S. Familial hypercholesterolemia. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The Metabolic and Molecular Bases of Inherited Disease. 7th edition:1995;1981-2030 McGraw-Hill, New York.
6. Moorjani S., Roy M., Gagné C., Davignon J., Brun D., Toussaint M. et al. Homozygous familial hypercholesterolemia among French Canadians in Québec Province. Arteriosclerosis. 9:1989;211-216.
7. Hobbs H.H., Brown M.S., Russell D.W., Davignon J., Goldstein J.L. Deletion in the gene for the low-density lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N. Engl. J. Med. 317:1987;734-737.
8. Minnich A., Roy M., Chamberland A., Lavigne J., Davignon J. New methods for rapid detection of low-density lipoprotein receptor and apolipoprotein B gene mutations causing familial hypercholesterolemia. Clin. Biochem. 28:1995;277-284.
9. Davignon J., Gregg R.E., Sing C.F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 8:1988;1-21.
10. Hopkins P.N., Wu L.L., Schumacher M.C., Emi M., Hegele R.M., Hunt S.C. et al. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2: evidence for a gene-gene interaction. Arterioscler. Thromb. 11:1991;1137-1146.
11. Hazzard W.R., Miller N., Albers J.J., Warnick G.R., Baron P., Lewis B. Association of isoapolipoprotein E3 deficiency with heterozygous familial hypercholesterolemia: implications for lipoprotein physiology. Lancet. i:1981;298-301.
12. 3 deficiency - report of two cases. Arteriosclerosis. 4:1984;124-129.
13. Sakuma N., Iwata S., Ikeuchi R., Ichikawa T., Hibino T., Kamiya Y. et al. Coexisting type III hyperlipoproteinemia and familial hypercholesterolemia: a case report. Metabolism. 44:1995;460-465.
14. Ziemer A., Goring H.D. Severe type III hyperlipoproteinemia with unusual lipoprotein phenotype in an adolescent patent. Hautarzt. 44:1993;538-544.
15. Feussner G., Dobmeyer J., Nissen H., Hansen T.S. Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type III hyperlipoproteinemia. Am. J. Med. Genet. 65:1996;149-154.
16. Morganroth J., Levy R.I., Fredrickson D.S. The biochemical, clinical and genetic features of type III hyperlipoproteinemia. Ann. Intern. Med. 82:1975;158-174.
17. Lipid Research Clinics Program. Manual of laboratory operations, Vol. 1: Lipid and lipoprotein analysis. US Department of Health, Education and Welfare. Publication no. 75-628 (NIH), Washington, DC. US Government Printing Office 1974;1-81.
18. Bouthillier D., Sing C.F., Davignon J. Apolipoprotein E phenotyping with a single gel method: application to the study of informative matings. J. Lipid Res. 24:1983;1060-1069.
19. Anonymous. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1333-1445.
20. Ferrières J., Sing C.F., Roy M., Davignon J., Lussier-Cacan S. Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia: sex-specific effects. Arterioscler. Thromb. 14:1994;1553-1560.
21. Ferrières J., Lambert J., Lussier-Cacan S., Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation. 92:1995;290-295.
22. Roy M., Sing C.F., Betard C., Davignon J. Impact of a common mutation of the LDL receptor gene, in French-Canadian patients with familial hypercholesterolemia, on means, variances and correlations among traits of lipid metabolism. Clin. Genet. 45:1995;59-67.
23. Neter J, Wasserman W, Kutner MH. Regression, analysis of variance and experimental designs. In: Anonymous, editor. Applied Linear Statistical Models, 3rd edition. Homewood IL: RD Irving, 1990.
24. Anonymous. Santé Québec: Faits saillants de l' enquête québécoise sur la santé cardio-vasculaire 1990. In: Ministère de la Santé et des Services Sociaux, editor. Gouvernement du Québec, 1994:159.
25. Feussner G., Wagner A., Kohl B., Ziegler R. Clinical features of type III hyperlipoproteinemia: analysis of 64 patients. Clin. Invest. 71:1993;362-366.
26. Schuster H., Kröner K.K., Keller C., Spengel F., Wolfram G., Zöllner N. Atherosclerosis of the carotid arteries documented by Duplex Scan as a predictor of coronary artery disease in familial hyperlipidemias. Klin. Wochenschr. 66:1988;65-68.
27. Spengel F.A., Kaess B., Keller C., Kröner K.K., Schreiber M., Schuster H. et al. Atherosclerosis of the carotid arteries in young patients with familial hypercholesterolemia. Klin. Wochenschr. 66:1988;65-68.
28. Wendelhag I., Wiklund O., Wikstrand J. Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia: ultrasonographic assessment of intima-media thickness and plaque occurrence. Arterioscler. Thromb. 13:1993;1404-1411.
29. Dobmeyer J., Lohrmann J., Feussner G. Prevalence and association of atherosclerosis at three different arterial sites in patients with type III hyperlipoproteinemia. Atherosclerosis. 119:1996;89-98.
30. Brown M.S., Goldstein J.L. Lipoprotein metabolism in the macrophage. Implications for cholesterol deposition in atherosclerosis. Annu. Rev. Biochem. 52:1983;223-261.
31. Mahley R.W. Atherogenic lipoproteins and coronary artery disease: concepts derived from recent advances in cellular and molecular biology. Circulation. 72:1985;943-947.
32. Rapp J.H., Lespine A., Hamilton R.L., Colyvas N., Chaumeton A.H., Tweedie-Hardman J. et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler. Thromb. 14:1994;1767-1774.
33. Dallongeville J., Roy M., Leboeuf N., Xhignesse M., Davignon J., Lussier-Cacan S. Apolipoprotein E polymorphism association with lipoprotein profile in endogenous hypertriglyceridemia and familial hypercholesterolemia. Arteriosclerosis. 11:1991;272-278.
34. Kotze M.J., De Villiers W.J.S., Steyn K., Kriek J.A., Marais A.D., Langenhoven E. et al. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler. Thromb. 13:1993;1460-1468.
35. Sass C., Giroux L.-M., Ma Y., Roy M., Lavigne J., Lussier-Cacan S. et al. Evidence for a cholesterol-lowering gene in a French-Canadian kindred with familial hypercholesterolemia. Hum. Genet. 96:1995;21-26.
36. 158→Cys) compared. Clin. Chem. 40:1994;1559-1566.
37. Lussier-Cacan S., Bard J.-M., Boulet L., Nestruck A.C., Grothé A.-M., Fruchart J.-C. et al. Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III. Atherosclerosis. 78:1989;167-182.
38. Packard C.J., Clegg R.J., Dominiczak M.H., Lorimer A.R., Shepherd J. Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects. J. Lipid Res. 27:1986;930-938.
39. Zhao S.-P., Smelt A.H.M., Van den Maagdenberg A.M.J.M., Van Tol A., Vroom T.F.F.P., Leuven J.A.G. et al. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158→Cys), E3-Leiden, and E2(Lys146→Gln), and effects of treatment with simvastatin. Arterioscler. Thromb. 14:1994;1705-1716.